Rini and colleagues provide additional data on bevacizumab and interferon-α in clear-cell carcinoma of the kidney; a comparison of these results with the findings from contemporary trials suggests that bevacizumab and interferon-α is another clinically useful treatment option for patients with metastatic renal-cell carcinoma.
